Categories
Change Password!
Reset Password!
Bencycloquidium bromide provides superior relief for runny nose symptoms and, when paired with mometasone furoate, offers greater symptom control in allergic rhinitis.
In a study led by Xian Li and other researchers, bencycloquidium bromide nasal spray (BBNS) was more effective than mometasone furoate nasal spray (MFNS) in reducing daily runny nose symptoms. Combined with MFNS, it provided greater relief of symptoms in those with moderate-to-severe persistent allergic rhinitis (AR) and a dominant runny nose symptom.
This multicenter, randomized controlled trial intended to explore the effectiveness of BBNS, MFNS, and the combination treatment. Participants were assigned to receive BBNS, MFNS, or a combination of both treatments over a 4-week period. The study tracked the average changes from baseline in key symptoms, including daily runny nose, sneezing, nasal itching, nasal congestion, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, and total nasal symptom score (TNSS). Additionally, exploratory endpoints and adverse events were evaluated.
The results were striking! BBNS alone led to a remarkable improvement in daily runny nose symptoms, outpacing MFNS by a notable margin (least-squares mean difference, –0.27). When BBNS was paired with MFNS, the volunteers experienced enhanced relief across multiple symptoms, including runny nose, nasal congestion, sneezing, TNSS, and RQLQ scores—with the exception of nasal itching.
Beyond symptom relief, BBNS also illustrated promise in reducing key inflammatory markers, such as eosinophilic cationic protein, eotaxin, vasoactive intestinal peptide, and interleukin-6 levels, suggesting a broader impact on allergic inflammation. Treatment-emergent adverse events were comparable across all groups, indicating that the BBNS and MFNS combination is generally well-tolerated.
This study not only highlights BBNS's superiority in easing daily runny nose symptoms but also positions the combination treatment as a potent strategy for tackling the broader spectrum of AR symptoms.
The Journal of Allergy and Clinical Immunology: In Practice
A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis
Xian Li et al.
Comments (0)